ILEVRO

This brand name is authorized in Canada, Ecuador, New Zealand, United States, South Africa

Active ingredients

The drug ILEVRO contains one active pharmaceutical ingredient (API):

1 Nepafenac UNII 0J9L7J6V8C - NEPAFENAC

Nepafenac is a non-steroidal anti-inflammatory and analgesic prodrug. After topical ocular dosing, nepafenac penetrates the cornea and is converted by ocular tissue hydrolases to amfenac, a nonsteroidal anti-inflammatory drug. Amfenac inhibits the action of prostaglandin H synthase (cyclooxygenase), an enzyme required for prostaglandin production. Read about Nepafenac

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ILEVRO Ophthalmic suspension	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
S01BC10	Nepafenac	S Sensory organs → S01 Ophthalmologicals → S01B Antiinflammatory agents → S01BC Antiinflammatory agents, non-steroids
Discover more medicines within S01BC10

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02411393
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 383-MEE-0714
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 17328
Country: US	FDA, National Drug Code	Identifier(s): 0065-1750
Country: ZA	Health Products Regulatory Authority	Identifier(s): 52/15.4/0575